“The intent of these relationships is to provide Amgen and Novartis with strategic proximity to Atlas Venture’s startup formation activities around innovative, potentially high-impact medicines, and catalyze future collaborations around translational research across Atlas Venture’s early-stage portfolio,” the company further explained in a statement. “Amgen and Novartis bring their deep knowledge in pharmaceutical R&D with Atlas Venture’s focus on creating and building new biomedical startups with experienced entrepreneurs.”

Atlas added that though this effort aims to bring venture and pharma interests together, the company maintains “full authority over funding strategy and investment decisions” it makes in the area. These agreements, in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners, are expected to create and/or fund more than 15 new biotech firms, the VC giant said.

In a statement, Amgen’s Sean Harper, M.D., evp of R&D, said that his firm “is very excited to partner with Atlas Venture, one of a small number of venture capital groups that truly focuses on creating value by translating groundbreaking science into new companies.” Added Novartis’ Mark Fishman, president of the firm’s Institutes for BioMedical Research: “We look forward to working with the Atlas team to build young startups that will hopefully one day lead to the development of new medicines for patients in need.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

41.2%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

23.5%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.